A Suspected Case of Silodosin-Induced Erythroderma
Tóm tắt
An 86-year-old man developed a suspected severe erythroderma during treatment with silodosin (dosage unknown) for benign prostatic enlargement. Two weeks after starting silodosin, he developed a total-body scaling dermatitis. A biopsy was planned but the patient improved at his subsequent visit and it was not taken. Silodosin was discontinued and the patient received UVB phototherapy, clobetasol ointment, and several bland and protective skin-care measures. One week after the initial presentation, the patient demonstrated improvement in his total-body scaling. Based on these findings, the patient was diagnosed with a suspected silodosin-induced erythroderma. Due to limitations in the patient’s clinical history and investigations, a Naranjo assessment score was not obtainable.
Tài liệu tham khảo
Watson Pharmaceuticals, Inc.: Watson receives US FDA approval for RAPAFLO(TM) (silodosin) for the treatment of benign prostatic hyperplasia (BPH). http://ir.actavis.com/phoenix.zhtml?c=65778&p=irol-newsArticle&ID=1207177. Accessed 10 Aug 2013.
Watson Pharmaceuticals, Inc.: Important safety information. 2013. https://www.rapaflo.com/hcp-role-primary.asp. Accessed 10 Aug 2013.
McVary, KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–8.
Wolff K, Johnson RA. Fitzpatrick’s color atlas and synopsis of clinical dermatology. 6th ed. New York: The McGraw Hill Companies, Inc; 2009.
Medscape: Silodosin (Rx)—Rapaflo. Drug interactions. http://reference.medscape.com/drug/rapaflo-silodosin-999100#3. Accessed 7 Oct 2014.
Okoduwa C, Lambert WC, Schwartz RA, et al. Erythroderma: review of a potentially life-threatening dermatosis. Indian J Dermatol. 2009;54(1):1–6.
Rubins AY, Hartmane IV, Lielbriedis YM, et al. Therapeutic options for erythroderma. Cutis. 1992;49(6):424–6.
Sigurdsson V, de Vries IJ, Toonstra J, et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol. 2000;27(9):436–40.
Sehgal VN, Srivastava G, Sardana K. Review erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol. 2004;43(1):39–47.
Umar SH, Kelly AP. Erythroderma (generalized exfoliative dermatitis). Medscape. 2012. http://emedicine.medscape.com/article/1106906-overview#a0104. Accessed 22 Sep 2013.
Rothe MJ, Bialy TL, Grant-Kels JM. Erythroderma. Dermatol Clin. 2000;18(3):405–15.
Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man”. Clin Dermatol. 2005;23:206–17.